Literature DB >> 31773798

Role of miR-106-mediated mitogen-activated protein kinase signaling pathway in oxidative stress injury and inflammatory infiltration in the liver of the mouse with gestational hypertension.

Zhihui Wang1, Xiufang Bao1, Limeng Song2, Yuying Tian3, Ping Sun1.   

Abstract

We aim to investigate the role of miR-106-mediated mitogen-activated protein kinase (MAPK) signaling pathway in oxidative stress (OS) injury and inflammatory infiltration in the liver of the mouse with gestational hypertension (GH). Ninety specific pathogen-free mice (Kunming species) during middle to late gestation were selected for the study. Fifteen mice were used as control, while the rest were used for establishing the GH model. The mice were assigned to six groups: normal group (normal gestation), model group (GH model), negative control group (GH model, intravenously injected with negative control vector), miR-106a-mimic group (GH model, intravenously injected with vector overexpressing miR-106a, which mimics the overexpression of endogenous mature miR-106a), SB203580 group (GH model, intravenously injected with MAPK pathway inhibitor SB203580), and miR-106a-mimic+SB203580 group (GH model, intravenously injected with SB203580 and vector overexpressing miR-106a). Fourteen days after electrical stimulation, all the groups except for the normal group had elevated blood pressure vs those on day 0 and 7. Compared with the normal group, the other groups had lower levels of miR-106a expression, nitric oxide, nitric oxide synthase, catalase, superoxide dismutase, S cell ratio, and interleukin-4 (IL-4) and IL-10 in the serum and liver as opposed to increased levels of blood pressure, p38MAPK mRNA expression, p-p38MAPK positive expression rate, protein expressions of p-p38MAPK, p-ERK, and p-JNK, H2 O2 and malondialdehyde in liver, G0/G1 cell ratio, apoptosis rate, and IL-6, interferon-γ (IFN-γ), and IFN-α in the serum and liver (all P < .05). The miR-106 overexpression or inhibiting MAPK signaling pathway can attenuate OS injury and inflammatory response in the liver of the mouse with GH, and the effect can be even better if both miR-106a overexpression and inhibiting MAPK pathway are applied. In conclusion, miR-106a overexpression can inhibit OS injury and inflammatory infiltration in the liver of the mouse with GH by mediating MAPK signaling pathway.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  MAP kinase signaling system; inflammation; liver; microRNAs; oxidative stress; pregnancy-induced hypertension

Year:  2019        PMID: 31773798     DOI: 10.1002/jcb.29552

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  Pre-treatment and continuous administration of simvastatin during sepsis improve metabolic parameters and prevent CNS injuries in survivor rats.

Authors:  Carlos Henrique Rocha Catalão; Anderson de Oliveira Souza; Nilton Nascimento Santos-Junior; Luis Henrique Angenendt da Costa; Jonathas Rodrigo Dos Santos; Luciane Carla Alberici; Maria José Alves Rocha
Journal:  Mol Cell Biochem       Date:  2022-05-23       Impact factor: 3.396

2.  NFKB1-mediated downregulation of microRNA-106a promotes oxidative stress injury and insulin resistance in mice with gestational hypertension.

Authors:  Yunxia Guo; Zhaofang Liu; Ming Wang
Journal:  Cytotechnology       Date:  2021-01-04       Impact factor: 2.058

3.  Differential Expression of Serum TUG1, LINC00657, miR-9, and miR-106a in Diabetic Patients With and Without Ischemic Stroke.

Authors:  Omayma O Abdelaleem; Olfat G Shaker; Mohamed M Mohamed; Tarek I Ahmed; Ahmed F Elkhateeb; Noha K Abdelghaffar; Naglaa A Ahmed; Abeer A Khalefa; Nada F Hemeda; Rania H Mahmoud
Journal:  Front Mol Biosci       Date:  2022-02-14

4.  Serum Level of miR-1 and miR-155 as Potential Biomarkers of Stress-Resilience of NET-KO and SWR/J Mice.

Authors:  Joanna Solich; Maciej Kuśmider; Agata Faron-Górecka; Paulina Pabian; Magdalena Kolasa; Beata Zemła; Marta Dziedzicka-Wasylewska
Journal:  Cells       Date:  2020-04-09       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.